Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 17

1.

Fluoro-pegylated chalcones as positron emission tomography probes for in vivo imaging of beta-amyloid plaques in Alzheimer's disease.

Ono M, Watanabe R, Kawashima H, Cheng Y, Kimura H, Watanabe H, Haratake M, Saji H, Nakayama M.

J Med Chem. 2009 Oct 22;52(20):6394-401. doi: 10.1021/jm901057p.

PMID:
19757822
2.

Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.

Brandt R, Hundelt M, Shahani N.

Biochim Biophys Acta. 2005 Jan 3;1739(2-3):331-54. Review.

3.

Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease.

Kung MP, Hou C, Zhuang ZP, Skovronsky D, Kung HF.

Brain Res. 2004 Oct 29;1025(1-2):98-105. Erratum in: Brain Res. 2005 Jan 21;1031(2):302.

PMID:
15464749
4.

PET imaging of amyloid in Alzheimer's disease.

Nordberg A.

Lancet Neurol. 2004 Sep;3(9):519-27. Review.

PMID:
15324720
5.

MRI and CSF studies in the early diagnosis of Alzheimer's disease.

de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H.

J Intern Med. 2004 Sep;256(3):205-23.

6.

Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease.

Wang Y, Klunk WE, Debnath ML, Huang GF, Holt DP, Shao L, Mathis CA.

J Mol Neurosci. 2004;24(1):55-62.

PMID:
15314250
7.

Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain.

Mathis CA, Wang Y, Klunk WE.

Curr Pharm Des. 2004;10(13):1469-92. Review.

PMID:
15134570
8.

Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography.

Klunk WE, Engler H, Nordberg A, Bacskai BJ, Wang Y, Price JC, Bergström M, Hyman BT, Långström B, Mathis CA.

Neuroimaging Clin N Am. 2003 Nov;13(4):781-9, ix. Review.

PMID:
15024961
9.

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B.

Ann Neurol. 2004 Mar;55(3):306-19.

PMID:
14991808
10.

Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice.

Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang GF, Mathis CA, Klunk WE, Hyman BT.

Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12462-7. Epub 2003 Sep 29.

11.

The relationship between amyloid and tau.

Hardy J.

J Mol Neurosci. 2003 Apr;20(2):203-6. Review.

PMID:
12794314
12.

Imaging amyloid-beta deposits in vivo.

Bacskai BJ, Klunk WE, Mathis CA, Hyman BT.

J Cereb Blood Flow Metab. 2002 Sep;22(9):1035-41. Review.

PMID:
12218409
13.

Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR.

Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):24-35.

PMID:
11790632
14.

A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events.

Heininger K.

Rev Neurosci. 2000;11 Spec No:213-328. Review.

PMID:
11065271
15.

Clinical features of Alzheimer's disease.

Förstl H, Kurz A.

Eur Arch Psychiatry Clin Neurosci. 1999;249(6):288-90. Review.

PMID:
10653284
16.

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L.

Neurology. 1991 Apr;41(4):479-86.

PMID:
2011243
17.

Alzheimer's disease: the amyloid cascade hypothesis.

Hardy JA, Higgins GA.

Science. 1992 Apr 10;256(5054):184-5. Review. No abstract available.

PMID:
1566067

Supplemental Content

Support Center